DCR-MYC: Additional Phase I data

Data from 18 evaluable patients with solid tumors, multiple myeloma or lymphoma in an open-label, dose-escalation, U.S. Phase I trial showed that 0.1-0.68 mg/kg IV DCR-MYC on days 1 and 8 of each 21-d...